Lipiodol
Drug
GUERBET LLC
Total Payments
$3.0M
Transactions
429
Doctors
99
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $592,095 | 49 | 25 |
| 2020 | $677,694 | 14 | 3 |
| 2019 | $561,705 | 107 | 40 |
| 2018 | $801,515 | 257 | 47 |
| 2017 | $397,469 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 39 | 91.5% |
| Consulting Fee | $142,128 | 22 | 4.7% |
| Travel and Lodging | $66,565 | 160 | 2.2% |
| Food and Beverage | $34,234 | 202 | 1.1% |
| Grant | $8,940 | 1 | 0.3% |
| Education | $3,646 | 4 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,160 | 1 | 0.1% |
Payments by Type
Research
$2.8M
39 transactions
General
$257,672
390 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Lipiodol an imaging Biomarker in patients with primary and metastic liver cancer | GUERBET LLC | $397,469 | 0 |
| Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver | GUERBET LLC | $310,766 | 0 |
| Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver | GUERBET LLC | $301,492 | 0 |
| Randomized Embolization Trial in Neuroendocrine Tumors | GUERBET LLC | $255,108 | 0 |
| Randomized Embolization Trial in Neuroendocrine Tu | GUERBET LLC | $173,937 | 0 |
| Pharmacokinetics of Doxorubicin in cTACE of Liver | GUERBET LLC | $156,537 | 0 |
| Phase II Trial of Lung Chemoembolization | GUERBET LLC | $117,469 | 0 |
| Intralymphatic Lipiodol Injection: Effect on the microscopic changes in lymph nodes and ducts and pu | GUERBET LLC | $88,825 | 0 |
| Lipiodol an imaging Biomarker in patients with pri | GUERBET LLC | $82,150 | 0 |
| Lipiodol Mediated Potentiation of Radiation Dose b | GUERBET LLC | $71,169 | 0 |
| Lipiodol Injection effect on microscopic changes in lymph nodes| ducts and pulmonary functions | GUERBET LLC | $71,060 | 0 |
| Chemoembolization of UM Hepatic mestastases using 300mg of BCNU Dissolved in Lipiodol followed by Gelfoam Embolization | GUERBET LLC | $55,931 | 0 |
| Lipiodol as an Imaging Biomarker in Patients With | GUERBET LLC | $41,075 | 0 |
| Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer | GUERBET LLC | $35,820 | 0 |
| Retrospective cTACE for HCC | GUERBET LLC | $11,626 | 0 |
| Retrospective C-TACE RFA | GUERBET LLC | $8,373 | 0 |
| A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination With Convention | GUERBET LLC | $5.00 | 0 |
Top Doctors Receiving Payments for Lipiodol — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Obstetrics & Gynecology | Loudonville, NY | $1,970 | 7 |
| , M.D | Gynecology | Southington, CT | $1,956 | 8 |
| , MD | Reproductive Endocrinology | Augusta, GA | $1,896 | 6 |
| , MD | Nuclear Radiology | Philadelphia, PA | $1,886 | 6 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $1,870 | 5 |
| , M.D | Diagnostic Radiology | Rochester, MN | $1,870 | 5 |
| , MD | Diagnostic Radiology | Los Angeles, CA | $1,859 | 4 |
| , MD, PHD | Vascular & Interventional Radiology | New York, NY | $1,819 | 5 |
| , MD | Obstetrics & Gynecology | Palo Alto, CA | $1,815 | 6 |
| , M.D | Obstetrics & Gynecology | Philadelphia, PA | $1,805 | 6 |
| , MD/PHD | Vascular & Interventional Radiology | Eau Claire, WI | $1,662 | 4 |
| , MD | Obstetrics & Gynecology | Chapel Hill, NC | $1,656 | 7 |
| , MD | Reproductive Endocrinology | Ann Arbor, MI | $1,552 | 6 |
| , MD | Vascular & Interventional Radiology | Indianapolis, IN | $1,376 | 5 |
| , MD | Diagnostic Radiology | Houston, TX | $1,328 | 6 |
| , MD | Obstetrics & Gynecology | Hershey, PA | $1,326 | 7 |
| , M.D | Diagnostic Radiology | Houston, TX | $1,303 | 4 |
| , MD | Obstetrics & Gynecology | Philadelphia, PA | $1,279 | 5 |
| , M.D | Diagnostic Radiology | Houston, TX | $1,253 | 4 |
| , MD | Reproductive Endocrinology | Hoffman Estates, IL | $1,223 | 4 |
| , MD, PHD | Vascular & Interventional Radiology | Portland, OR | $1,206 | 4 |
| , M.D | Vascular & Interventional Radiology | Chicago, IL | $1,031 | 5 |
| , MD | Specialist | New York, NY | $1,000 | 1 |
| , MD, MPH | Vascular & Interventional Radiology | Durham, NC | $977.25 | 7 |
| , MD | Diagnostic Radiology | Ann Arbor, MI | $958.85 | 5 |
Ad
Manufacturing Companies
- GUERBET LLC $3.0M
Product Information
- Type Drug
- Total Payments $3.0M
- Total Doctors 99
- Transactions 429
About Lipiodol
Lipiodol is a drug associated with $3.0M in payments to 99 healthcare providers, recorded across 429 transactions in the CMS Open Payments database. The primary manufacturer is GUERBET LLC.
Payment data is available from 2017 to 2023. In 2023, $592,095 was paid across 49 transactions to 25 doctors.
The most common payment nature for Lipiodol is "Unspecified" ($2.8M, 91.5% of total).
Lipiodol is associated with 17 research studies, including "Lipiodol an imaging Biomarker in patients with primary and metastic liver cancer" ($397,469).